The US Food and Drug Administration (FDA) has granted Fast Track designation to Exelixis’ renal cell carcinoma (RCC) drug. The agency provided fast track status for Exelixis’ investigational cabozantinib for the treatment of patients with advanced RCC who have received one prior therapy. The news sent the company’s shares up …